Progyny, Inc. (PGNY), a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers.

The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015.

Progyny reported Quarter December 2020 earnings of $0.07 per share on revenue of $100.3 million. The consensus earnings estimate was $0.06 per share. Revenue grew 54.0% on a year-over-year basis.

The company said it expects first quarter earnings of $0.07 to $0.09 per share on revenue of $117.0 million to $122.0 million and 2021 earnings of $0.29 to $0.36 per share on revenue of $520.0 million to $540.0 million. The current consensus estimate is earnings of $0.11 per share on revenue of $125.8 million for the quarter ending March 31, 2021 and earnings of $0.40 per share on revenue of $537.7 million for the year ending December 31, 2021.

This stock's chart formation suggests that share prices should be moving higher and breaking out of their "wedge formation".